Compare SRRK & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRRK | HLNE |
|---|---|---|
| Founded | 2012 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.7B |
| IPO Year | 2018 | 2017 |
| Metric | SRRK | HLNE |
|---|---|---|
| Price | $45.04 | $100.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $55.40 | ★ $168.33 |
| AVG Volume (30 Days) | ★ 1.1M | 885.8K |
| Earning Date | 03-03-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | N/A | ★ 41.64 |
| EPS | N/A | ★ 3.98 |
| Revenue | N/A | ★ $712,963,000.00 |
| Revenue This Year | N/A | $9.81 |
| Revenue Next Year | $449.79 | $19.69 |
| P/E Ratio | ★ N/A | $25.79 |
| Revenue Growth | N/A | ★ 28.73 |
| 52 Week Low | $22.71 | $92.77 |
| 52 Week High | $49.82 | $179.19 |
| Indicator | SRRK | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.17 | 38.32 |
| Support Level | $41.54 | $98.00 |
| Resistance Level | $48.29 | $135.92 |
| Average True Range (ATR) | 2.49 | 4.30 |
| MACD | -0.28 | 0.92 |
| Stochastic Oscillator | 62.43 | 49.37 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.